CV Sciences (CVSI) Receives New Coverage from Analysts at Roth Capital

Investment analysts at Roth Capital began coverage on shares of CV Sciences (OTCMKTS:CVSI) in a report issued on Thursday, BenzingaRatingsTable reports. The brokerage set a “buy” rating and a $9.00 price target on the stock. Roth Capital’s price objective indicates a potential upside of 89.87% from the stock’s previous close.

Several other research analysts have also recently weighed in on CVSI. Zacks Investment Research upgraded CV Sciences from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Northland Securities reiterated a “buy” rating on shares of CV Sciences in a research report on Thursday, May 9th.

Shares of CV Sciences stock opened at $4.74 on Thursday. CV Sciences has a 1 year low of $0.92 and a 1 year high of $9.20. The firm has a market cap of $467.89 million, a price-to-earnings ratio of 52.67 and a beta of -0.93. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.97 and a quick ratio of 2.27.

CV Sciences (OTCMKTS:CVSI) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.12). The business had revenue of $14.91 million during the quarter, compared to analyst estimates of $14.51 million. On average, sell-side analysts forecast that CV Sciences will post 0.12 EPS for the current fiscal year.

CV Sciences Company Profile

CV Sciences, Inc operates as a life science company. It operates through two segments, Consumer Products and Specialty Pharmaceuticals. The Consumer Products segment manufactures, markets, and sells consumer products containing hemp-based cannabidiol oil under the PlusCBD brand in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.

Featured Article: 12b-1 Fees

Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with's FREE daily email newsletter.

Leave a Reply